PA8540601A1 - Derivados de alcoxicarbonilaminotetrazolil fenilo o acido alcoxicarbonilamino benzoico como antagonistas ip - Google Patents

Derivados de alcoxicarbonilaminotetrazolil fenilo o acido alcoxicarbonilamino benzoico como antagonistas ip

Info

Publication number
PA8540601A1
PA8540601A1 PA20028540601A PA8540601A PA8540601A1 PA 8540601 A1 PA8540601 A1 PA 8540601A1 PA 20028540601 A PA20028540601 A PA 20028540601A PA 8540601 A PA8540601 A PA 8540601A PA 8540601 A1 PA8540601 A1 PA 8540601A1
Authority
PA
Panama
Prior art keywords
alcoxicarbonylamine
alcoxicarbonilaminotetrazolil
phenyll
antagonists
benzoic
Prior art date
Application number
PA20028540601A
Other languages
English (en)
Inventor
Francisco Javier Lopez-Tapia
Dov Nitzan
Counde O'yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8540601A1 publication Critical patent/PA8540601A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

ESTA INVENCION SE REFIERE A LOS COMPUESTOS QUE SON GENERALMENTE ANTAGONISTAS DEL RECEPTOR IP Y QUE ESTAN REPRESENTADOS POR LA FORMULA GENERAL I EN DONDE G1 ES SELECCIONADO DE LOS GRUPOS a, b1 y b2; Y A Y G2 SON TAL COMO SE HAN DEFINIDO EN LA ESPECIFICACION; O ISOMEROS INDIVIDUALES, MEZCLAS RECEMICAS O NO RACEMICAS DE ISOMEROS, O SALES O SOLVATOS FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS. LA INVENCION ADEMAS SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS COMPUESTOS, SU USO COMO AGENTES TERAPEUTICOS, Y LOS METODOS DE LA PREPARACION DE LOS MISMOS.
PA20028540601A 2001-03-02 2002-02-26 Derivados de alcoxicarbonilaminotetrazolil fenilo o acido alcoxicarbonilamino benzoico como antagonistas ip PA8540601A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27287201P 2001-03-02 2001-03-02
US31255901P 2001-08-15 2001-08-15

Publications (1)

Publication Number Publication Date
PA8540601A1 true PA8540601A1 (es) 2002-09-30

Family

ID=26955795

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028540601A PA8540601A1 (es) 2001-03-02 2002-02-26 Derivados de alcoxicarbonilaminotetrazolil fenilo o acido alcoxicarbonilamino benzoico como antagonistas ip

Country Status (16)

Country Link
US (1) US6903086B2 (es)
EP (1) EP1379516B1 (es)
JP (1) JP4018985B2 (es)
KR (1) KR100559015B1 (es)
CN (1) CN1256334C (es)
AR (1) AR033430A1 (es)
AT (1) ATE309994T1 (es)
AU (1) AU2002253061B2 (es)
BR (1) BR0207795A (es)
CA (1) CA2438737A1 (es)
DE (1) DE60207399T2 (es)
ES (1) ES2252443T3 (es)
MX (1) MXPA03007865A (es)
PA (1) PA8540601A1 (es)
PE (1) PE20020905A1 (es)
WO (1) WO2002070500A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
WO2004071508A1 (en) * 2003-02-14 2004-08-26 Medical Research Council Ip receptor antagonists for the treatment of pathological uterine conditions
GB0503056D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
BRPI0815634B1 (pt) * 2007-08-21 2024-01-09 Firmenich Incorporated Receptores t2r humanos que respondem a compostos amargos que causam gosto amargo nas composições e seus métodos de produção, bem como método de redução ou alívio do sabor amargo em uma composição, composição de alimento, bebida ou medicamento ou composição de um produto nãocomestível
US8076491B2 (en) * 2007-08-21 2011-12-13 Senomyx, Inc. Compounds that inhibit (block) bitter taste in composition and use thereof
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US9321745B2 (en) 2013-03-12 2016-04-26 Allergan, Inc. Inhibition of neovascularization by inhibition of prostanoid IP receptors
WO2014143591A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
CN106496036A (zh) * 2016-09-29 2017-03-15 福建天富生物科技发展有限公司 一种抗凝血药物中间体5‑甲氧基‑2‑硝基苯甲酸的制备方法
US20200383967A1 (en) * 2017-08-07 2020-12-10 Hiroshima University Novel Anthranilic Acid-Based Compound, and Pin1 Inhibitor, Therapeutic Agent for Inflammatory Diseases and Therapeutic Agent for Cancer That Use the Same
CA3091027A1 (en) 2018-02-02 2019-08-08 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
CN108774183A (zh) * 2018-08-03 2018-11-09 成都苑东生物制药股份有限公司 一种乙二醇类化合物的制备方法
EP4119138A1 (en) * 2021-07-12 2023-01-18 Universität Hamburg Dhodh inhibitors and their use as antiviral agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6184242B1 (en) 1997-09-04 2001-02-06 Syntex Usa (Llc) 2-(substituted-phenyl)amino-imidazoline derivatives
US6320078B1 (en) 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
CA2339123A1 (en) 1998-07-31 2000-02-10 Nippon Soda Co., Ltd. Phenylazole compounds, process for producing the same and drugs for hyperlipemia
CZ20023422A3 (cs) * 2000-03-16 2003-01-15 F. Hoffmann-La Roche Ag Deriváty karboxylových kyselin jako antagonisté IP

Also Published As

Publication number Publication date
ATE309994T1 (de) 2005-12-15
AU2002253061B2 (en) 2005-04-07
US20020165235A1 (en) 2002-11-07
DE60207399T2 (de) 2006-08-03
EP1379516B1 (en) 2005-11-16
ES2252443T3 (es) 2006-05-16
MXPA03007865A (es) 2003-12-04
KR100559015B1 (ko) 2006-03-10
CA2438737A1 (en) 2002-09-12
DE60207399D1 (de) 2005-12-22
BR0207795A (pt) 2004-03-23
KR20040023591A (ko) 2004-03-18
WO2002070500A1 (en) 2002-09-12
JP2004529899A (ja) 2004-09-30
EP1379516A1 (en) 2004-01-14
CN1527824A (zh) 2004-09-08
JP4018985B2 (ja) 2007-12-05
AR033430A1 (es) 2003-12-17
US6903086B2 (en) 2005-06-07
PE20020905A1 (es) 2002-10-19
CN1256334C (zh) 2006-05-17

Similar Documents

Publication Publication Date Title
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
GT199900008A (es) Compuestos 4-(2-ceto-1-benzilimidazolinil) piperidina como agonistas del receptor orl1
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
ECSP034640A (es) Derivados de feniletenilo o feniletinilo como antagonistas del receptor del glutamato
ECSP066643A (es) PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
BR0109235A (pt) Derivados do ácido carboxìlico como antagonistas ip
CR7069A (es) Derivados de pirazol para el tratamiento de vih
BR0307406A (pt) Indóis substituìdos como agonistas alfa-1
ECSP045519A (es) Nuevos derivados de quinuclidina-amida
MA26904A1 (fr) Aminoalkyl 1-lactames substituees et leur utilisation en tant qu'antagonistes du recepteur muscarinique.
UY28692A1 (es) Nuevos derivados de quinolina
ES2158814B1 (es) Derivados de pirrolidina antagonistas del receptor ccr-3
PA8540601A1 (es) Derivados de alcoxicarbonilaminotetrazolil fenilo o acido alcoxicarbonilamino benzoico como antagonistas ip
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
PA8589601A1 (es) Derivados de indazol como antagonistas del crf
MA26906A1 (fr) Aminoalkyl 1-lactames substituees et leur utilisation en tant qu'antagonistes du recepteur muscarinique
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
BR0214695A (pt) Derivados de pirazol com anel fundido
MXPA04005076A (es) Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico.
BR0214649A (pt) Derivados de aminotetralina como antagonistas do receptor muscarìnico
AR030788A1 (es) Antagonistas de receptores de taquiquinina zwitterionica
RS56104A (en) Imidazoquinoline derivatives
UY27194A1 (es) Derivados de alcoxicarbonilaminotetrazolil fenilo o acido alcoxicarbonilamino benzoico como antagonistas de p.
AR021924A1 (es) BENZISOXAZOLES Y FENONAS COMO ALFA-2-ANTAGONISTAS , UN PROCESO PARA SU PREPARACIoN , COMPOSICIONES FARMACÉUTICAS Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO.